Oregon Psilocybin Services
16,000+ clients served
Oregon Psilocybin Services launched in January 2023 as the world's first state-regulated legal psilocybin program. As of Q3 2025, more than 16,000 clients have accessed licensed facilitator sessions. No prescription or diagnosis required.
Oregon Health Authority Data Dashboard, Q3 2025
23 active centers
licensed service centers operating as of Q3 2025 (out of 35 total licensed)
366 facilitators
licensed psilocybin facilitators statewide, a new state-certified profession created by Measure 109
No prescription
adults 21+ may access the program without a doctor's referral, diagnosis, or medical clearance
Oregon Health Authority Data Dashboard, Q3 2025
View as image ↗Oregon Psilocybin Services is the world's first state-regulated legal psilocybin program. Created by Measure 109, which Oregon voters passed in November 2020 with 56% of the vote, the program opened to the public in January 2023 after two years of rulemaking by the Oregon Health Authority. Any adult 21 or older can access a professionally facilitated psilocybin session at a licensed service center, without a prescription, medical referral, or qualifying diagnosis.
As of Q3 2025, the Oregon Health Authority reports more than 16,000 clients served, $1.7 million in revenue, and 37,000-plus psilocybin products sold through 23 active service centers statewide. A 2023 review in JAMA Psychiatry by Siegel and colleagues described Oregon's legislation as the most consequential psychedelic drug reform in US history: the first to create a fully regulated legal framework rather than decriminalizing possession without creating a supervised access system.[1]
This article explains how the program works, what a session looks like, who can access it, what it costs, and what the early outcomes data shows. For background on psilocybin's legal status at the federal level, see Psilocybin's Schedule I Status: History and Controversy. For a comparison of Oregon's approach with Colorado's newer model, see How Colorado's Psychedelic Law Differs from Oregon. For a complete overview of all current legal psilocybin access pathways in the US, see Legal Psilocybin Access Before FDA Approval: All Current Options.
Key Takeaways
- Oregon Measure 109 passed in November 2020 with 56% of the vote, creating the world's first state-regulated legal psilocybin program; the program launched for public access in January 2023 following two years of regulatory development
- Adults 21+ can access licensed psilocybin facilitation sessions without a prescription, medical referral, or qualifying diagnosis; the program intentionally removed medical gatekeeping
- As of Q3 2025, more than 16,000 clients have been served through 23 of 35 licensed service centers, with 366 licensed facilitators statewide and $1.7 million in total program revenue
- The program follows a three-phase model: preparation (1-2 sessions, may be virtual), administration (6-8 hours at a licensed center, average 24.44mg psilocybin in Q1 2025, maximum 50mg), and integration (offered within 72 hours post-session)
- Single-session costs range from $1,200 to $3,500; a $10,000 annual service center license fee is a primary factor in why 12 of 35 licensed centers have closed or are not operating
- A February 2026 naturalistic preprint study of 91 Oregon program participants (not yet peer-reviewed) found significant improvements in depression, anxiety, and wellbeing scores at 30 days post-session
What Oregon Psilocybin Services Is and How It Came to Exist
Psilocybin remains a Schedule I controlled substance under federal law, which means Oregon's program does not legalize psilocybin in a general sense. Measure 109 created a state-regulated framework within which licensed service centers may legally facilitate supervised psilocybin sessions for adults 21 and older. Outside that framework, psilocybin remains illegal in Oregon.
The program's design reflects a deliberate choice. The Measure 109 framework does not classify psilocybin facilitation as medical treatment and does not require a medical provider's oversight. Facilitators are not required to be licensed healthcare professionals. Participants do not need a diagnosis, prescription, or insurance approval. The program was designed for broad adult access within a supervised, regulated environment.
Siegel and colleagues' 2023 analysis in JAMA Psychiatry characterized the policy landscape: Oregon created something that had not existed before, a state-licensed profession (the psilocybin facilitator) with no equivalent in any other regulatory framework, trained and authorized to provide supervised psilocybin experiences as a standalone wellness service rather than as a component of psychiatric treatment.[1]
The program is also intentionally not a medical treatment. Facilitators may not provide psychotherapy during sessions, may not make medical diagnoses, and may not prescribe. They provide presence, support, and safety monitoring during the psilocybin experience. This structure was chosen to make the program accessible without requiring health insurance, a mental health provider, or a qualifying condition. It also means the program is not designed to treat specific disorders; it is designed to provide a supervised psilocybin experience in a safe, legal environment.
A New Profession: How Oregon Created the Licensed Psilocybin Facilitator
The Oregon Psilocybin Facilitator license is a new professional category created specifically by Measure 109 and the subsequent Oregon Health Authority rulemaking. Facilitators are not required to hold any prior healthcare license, though many do.
To become a licensed facilitator, applicants must complete an Oregon Health Authority-approved training program of 160 or more hours, pass a criminal background check, pass a licensing exam, and pay an annual license fee of $2,000 (reduced to $1,000 for veterans and recipients of public assistance). As of Q3 2025, 366 people hold active facilitator licenses, out of 572 total applications received since the program launched.
The training programs approved by the Oregon Health Authority cover psilocybin pharmacology, session facilitation techniques, screening protocols, trauma-informed approaches, and legal compliance. The Oregon Health Authority maintains oversight of both training programs and facilitators through an ongoing license renewal and compliance process.
A parallel license category, the Service Center License, authorizes specific physical locations to operate as regulated psilocybin venues. Service centers pay $10,000 per year for their license and must comply with ongoing operational requirements including security, product sourcing from licensed manufacturers, and record-keeping. As of Q3 2025, 35 service center licenses have been issued, but only 23 are actively operating. The $10,000 annual fee, combined with facility rental, compliance costs, and the challenge of maintaining a sustainable client base in a low-awareness market, has been cited as a primary reason for closures.
The Three-Phase Program: What Participants Experience
Oregon's regulatory framework structures the psilocybin service into three required phases.
Phase 1: Preparation. Before any psilocybin is administered, facilitators must conduct one or more preparation sessions with the client. These sessions may be in-person at the service center or conducted virtually. The preparation phase covers informed consent, a medical and psychological intake screening, safety planning (particularly for individuals with certain medical histories or medications), and discussion of intentions, expectations, and dosage. There is no requirement for a minimum number of preparation sessions, but facilitators must complete the intake process and document informed consent before the administration session.
Phase 2: Administration. The psilocybin administration session must take place at a licensed service center. Sessions run approximately 6 to 8 hours, reflecting the natural duration of the psilocybin experience. Oregon Health Authority rules allow a maximum administered dose of 50 milligrams of psilocybin per session. In practice, the average dose used in Q1 2025 was 24.44 milligrams, roughly half the maximum, suggesting most facilitators and clients use moderate doses for initial sessions. Curated music is commonly played throughout. The facilitator maintains presence and observation throughout the session and intervenes if safety concerns arise. Clients may not drive themselves home.
Phase 3: Integration. Within 72 hours of the administration session, facilitators must offer an integration session. Integration is optional for clients but must be offered. The integration session allows clients to process the experience, review any safety plan elements, and receive referrals to community resources including licensed mental health providers if indicated. Some service centers offer extended multi-session programs that include multiple administration sessions with ongoing integration support.
For a step-by-step practical guide to what happens in each phase, see What Happens at an Oregon Psilocybin Session: A Guide.
Who Is Using Oregon's Program and What Early Outcomes Show
The Oregon Health Authority collects demographic and program data from service centers and reports it quarterly. As of Q3 2025, the program has served more than 16,000 clients since launching in January 2023. The Q1-Q3 2025 period alone accounted for 4,577 clients.
The cancer patient population is one specific group for whom Oregon's program has opened access that would otherwise require enrollment in a clinical trial. A 2024 review by Bellman in the journal Cancers examined psilocybin use for depression in cancer patients following Oregon's program approval, documenting that the Oregon framework allows cancer patients with depression to access psilocybin through the regulated program without requiring trial enrollment or clinical diagnosis requirements.[2]
The first formal outcomes study of Oregon program participants was circulated in February 2026 as a preprint on medRxiv (not yet peer-reviewed). The researchers followed 91 participants who completed sessions at Oregon licensed service centers between March 2024 and April 2025. The sample had a median age of 43, was 52% male, and 46.6% were taking psychiatric medications at enrollment. Before their sessions, 69.2% of participants reported mild-to-severe depression, 67.0% reported mild-to-severe anxiety, and 93.2% reported low or very low wellbeing. At 30 days post-session, the study reported significant improvements across all three outcome measures (p less than 0.001).
The preprint status of this study requires honest acknowledgment. A preprint has not completed peer review and its methods and conclusions are not yet independently validated. The study has no control group, so improvements over 30 days cannot be attributed definitively to the psilocybin session rather than to expectation effects, natural variation, or selection bias (people who seek out the program may have characteristics that predict improvement regardless of treatment). The naturalistic design is what it is: real-world data with real-world limitations.
What the data establishes: a prospective outcomes study from Oregon's actual program now exists. It has methodological limitations, but it is the first of its kind from any regulated psilocybin access program in the world. For a detailed analysis of this data and its limitations, see Oregon Psilocybin Data: Early Results from the First Licensed Centers.
The Cost and Access Challenge: Why 12 Service Centers Have Closed
The program faces a structural challenge that sits at the intersection of cost, awareness, and market scale.
The Oregon Health Authority reports that fewer than one in five Oregonians with a diagnosis that might benefit from psilocybin therapy are aware that the program exists. The program launched with limited public outreach and is not integrated into healthcare pathways in any systematic way. Potential clients find it primarily through word of mouth, online research, or practitioners who mention it.
For clients who do find the program, cost is a significant barrier. A single-session experience including preparation and integration typically costs $1,200 to $3,500. Multi-session programs cost $3,000 to $6,000. No insurance coverage exists for these services. Oregon's program includes no public funding for subsidized access, and while some service centers offer sliding scale fees, the operational economics of running a licensed center constrain how much discount is sustainable.
Service centers face their own cost structure: $10,000 per year for the facility license, facility rental, employee costs, compliance documentation, and psilocybin product costs from licensed manufacturers. With relatively low session volumes (a function of low public awareness and high client costs), many service centers cannot achieve the revenue needed to remain operational. Of 35 service center licenses issued since 2023, 12 are not actively operating as of Q3 2025.
The workforce picture shows an inverse mismatch: 366 licensed facilitators exist, but only 23 service centers are open. Many trained facilitators are not finding consistent work, while clients in underserved areas may have limited service center options. This mismatch is a structural outcome of the regulatory model, which created a facilitator profession faster than a sustainable service center market.
For a full breakdown of program costs for both participants and facilitators, see Oregon Psilocybin Costs, Licensing, and Access. For what other states and countries have learned from these structural challenges, see Lessons from Oregon: What Other States Can Learn.
Oregon Psilocybin Services Program: What Peer-Reviewed Research Says
The peer-reviewed literature on Oregon's specific program is still small, reflecting how recently the program launched. The primary academic value of the program, for now, is the policy and regulatory model it represents rather than a mature outcomes literature.
The Siegel et al. 2023 JAMA Psychiatry analysis reviewed Oregon's legislation alongside Colorado's Proposition 122 and the broader US state-level psychedelic reform landscape.[1] The authors noted that Oregon's framework specifically declined to medicalize psilocybin services, a choice that distinguishes it from both clinical trial models and from Colorado's approach, which allows licensed clinicians to integrate psilocybin facilitation into existing clinical practices. This policy distinction has consequences: Oregon's program is more broadly accessible on paper (no medical requirement) but constrained in practice by cost and awareness.
The Bellman 2024 review documented a specific access pathway that Oregon's program opens for people who would not otherwise qualify for clinical trial enrollment.[2] Cancer patients with treatment-resistant depression face a challenging clinical landscape: available medications are often less effective in this population, and psilocybin clinical trials have strict enrollment criteria. Oregon's regulated program creates a legal pathway for this population to access facilitated psilocybin outside the clinical trial framework, with facilitator training and safety oversight replacing clinical protocol supervision.
For a broader look at the expanded access pathway that provides an alternative legal route outside Oregon, see Expanded Access Programs for Psilocybin: How They Work.
The Bottom Line
Oregon Psilocybin Services launched in January 2023 as the world's first state-regulated legal psilocybin program, created by Measure 109 (passed November 2020 with 56% of votes). Adults 21+ access professionally facilitated sessions at licensed centers without a prescription or diagnosis. As of Q3 2025, more than 16,000 clients have been served through 23 active service centers, with 366 licensed facilitators operating statewide. The three-phase program includes preparation, a 6-8 hour administration session (average 24.44mg psilocybin), and integration. A 2026 naturalistic preprint study of 91 participants found significant improvements in depression, anxiety, and wellbeing at 30 days. This is the first outcomes data from the actual program, though not yet peer-reviewed and without a control group. The program faces sustained challenges from high costs ($1,200-$3,500 per session), low public awareness, and service center closures tied to the $10,000 annual license fee.
Frequently Asked Questions
Sources & References
- 1RTHM-01791·Siegel, Joshua S et al. (2023). “Psychedelic Drug Legislative Reform and Legalization in the US..” JAMA psychiatry.Study breakdown →PubMed →↩
- 2RTHM-01858·Bellman, Val (2024). “Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon..” Cancers.Study breakdown →PubMed →↩